To include your compound in the COVID-19 Resource Center, submit it here.

Vertex gains on telaprevir docs

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) gained $4.88 (10%) to $52.92 on Tuesday after FDA reviewers agreed that telaprevir is effective for treating HCV in briefing documents

Read the full 254 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE